Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Medical Nutrition USA, Inc. (NASDAQ: MDNU), a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat™, a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).

C-diff is a bacterium that causes diarrhea and more serious intestinal conditions. It is one of the chief causes of hospital-acquired diarrhea in the U.S., responsible for approximately three million cases per year of diarrhea and colitis treated at an annual cost of more than $1.1 billion.

Both C-diff and AAD pose serious risks to the health of elderly and frail patients from the wasting effects of diarrhea and intestinal damage. The likelihood that such conditions will arise in this population is increased when patients take antibiotics, which can eliminate the beneficial intestinal microbiota that help prevent the onset of AAD and C-diff.

Diff-Stat™, which is available as a powder or as a chewable tablet, contains a combination of clinically proven ingredients that help combat the effects of antibiotics on intestinal microbiota by providing increased beneficial bacteria to the colon, destroying toxins and toxin binding sites and stimulating the growth of beneficial bacteria.

SOURCE: Medical Nutrition USA, Inc.